A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs RBD 5044 (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Ribocure Pharmaceuticals
- 03 Feb 2025 New trial record